- 14 March
-
At the end of the last year, Novouralsk-based Medsintez Plant turned 20 years old. Alexander Petrov, Chairman of the plant's Board of Directors, told Regions of Russia about the impressive successes that the company has achieved over the years and its ambitious plans for the future.
- 22 January
-
In 2023, the Medsintez Plant, in collaboration with the Promomed Group of Companies, launched the production of a full cycle of hypoglycemic drugs Enligria (liraglutide) and Quincenta (semaglutide) used in treating type II diabetes mellitus, including in patients with obesity and overweight or cardiovascular disease. The preparations are available in the most convenient and familiar for patients dosage form – a disposable prefilled injection and have already been supplied to pharmacies.
- 13 December
-
Medsintez Plant LLC presented the latest biotechnological developments of pharmaceuticals at the largest international scientific and practical forum in the field of medicine and health care Russian Health Care Week — 2023 held from December 4 to December 8 in Moscow. The main purpose of the Forum is to facilitate the implementation of the national projects “Healthcare” and “Demography”, “Tourism and Hospitality Industry”, the federal project “Development of Medical Services Export”, as well as summarizing the results of the Year of Science and Technology in Medicine.
- 04 October
-
On September 27, as part of the business program of the GMP conference with international participation, Alexander Petrov, Chairman of the Board of Directors of Medsintez Plant LLC, took part in a Plenary Session on the issues of regulating the circulation of medicines in Russia and the EAEU, developing import independence, and increasing export potential. The session was attended by representatives of the Ministry of Industry and Trade of the Russian Federation, the Minister of Health of the Republic of Nicaragua, the WHO Representative in Russia, a Representative of the Serbian Ministry of Health and other Russian and foreign experts. Mr. Petrov spoke about the problems that Russian pharmaceutical companies face when entering international markets and suggested possible solutions.
- Home
- Cluster members
- Medsintez Plant LLC
Medsintez Plant LLC
Medsintez Plant LLC is a modern full-cycle biotechnological enterprise for development and production of pharmaceutical products complying with the international GMP requirements and ISO standards. The Medsintez Plant has been present on the Russian market for 20 years and is an active participant of drug import substitution programs in the Russian Federation.
The company produces genetically engineered and analogue human insulins Rosinsulin, a veterinary insulin Vinsuvet, a recombinant human follicle-stimulating hormone for the treatment of infertility Primapur, an innovative antiviral drug Triazavirin, hypoglycemic drugs Liraglutide and Semaglutide, infusion solutions and solutions for automated apheresis, as well as substances produced through chemical and biotechnological synthesis.
Main products of the enterprise are genetically engineered and analogue human insulins Rosinsulin, produced in cartridges, vials and pre-filled injection pens. The enterprise implements fully integrated production of the whole product range of genetically engineered human insulin Rosinsulin and analogue human insulins Rosinsulin Aspart R and Rosinsulin Glargine made of our own APIs. The plant also produces the first Russian veterinary species-specific insulin Vinsuvet, separately for cats and for dogs. In 2023, the Plant launched the production of a full cycle of hypoglycemic drugs for treating type II diabetes mellitus: Liraglutide and Semaglutide.
Triazavirin is a direct-acting antiviral drug developed by Russian scientists based on the original molecule. It is effective for the treatment and prevention of viral diseases, has a wide range of direct antiviral activity against RNA viral infections such as influenza, acute respiratory viral infection, COVID-19. Triazavirin is recommended by the Ministry of Health of the Russian Federation for treatment of influenza and ARVI in adults, and is the only direct-acting drug approved for prevention of COVID-19. Today, the company is developing a complex of antiviral drugs.
Primapur is the first Russian drug of recombinant human follicle-stimulating hormone, used in the in vitro fertilization and included in the List of Vital and Essential Drugs. Primapur is available in the form of an easy-to-use disposable injection pen. Today, the company is developing other hormonal drugs, used in a complex of assisted reproductive technologies, such as recombinant human chorionic gonadotropin and Cetrorelix, which will ensure the drug safety in this area in Russia and enable it not to depend on import supplies.
One of the major directions for development of the Medsintez Plant is contract manufacturing. Among partners of the enterprise are the largest international pharmaceutical companies such as Bayer, STADA, iVFarma, Promomed, etc.
High-tech Russian production at the Medsintez Plant ensures a high level of quality and safety of manufactured medicines. The company’s products are supplied to all regions of Russia. The production capacity of the plant is enough to cover 100% of the country’s needs for such vital drugs as insulin and FSH, as well as to provide major support to the country during epidemics and pandemics of RNA viral infections.
15, Torgovaya St., Novouralsk, Sverdlovsk Region, Russia
Тel.: +7 (34370) 2-50-61
e-mail: medsintez@mail.ru
.jpg)
